High inhaler resistance does not limit successful inspiratory maneuver among patients with asthma or COPD

References

• Price D, Harrow B, Small M, et al. Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. World Allergy Organ J. 2015;8:26.
   PubMed Web of Science ®Google Scholar
• Gillette C, Rockich-Winston N, Kuhn JA, et al. Inhaler technique in children with asthma: a systematic review. Acad Pediatr. 2016;16(7):605–615.
   PubMed Web of Science ®Google Scholar
• Benedick. Montreal protocol on substances that deplete the ozone layer medical and chemical technical options committee. 2018 Assessment report (2018) doi:10.1163/15718069620847781.
   Google Scholar
• Zarei S, Mirtar A, Andresen B, et al. Modeling the airflow in a lung with cystic fibrosis. J Non-Equilib Thermodyn. 2013;38(2). DOI:10.1515/jnetdy-2012-0019
   Web of Science ®Google Scholar
• Clark ARR, Hollingworth AMM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers — implications for in vitro testing. J Aerosol Med. 1993;6:99–110.
   PubMedGoogle Scholar
• Harris D. Testing inhalers. Pharmaceutical technology Europe. 2007;29–35.
   Google Scholar
• Harris D. What are the implications of human lung power on dpi design? Respir Drug Delivery. 2006;2006:537–540.
   Google Scholar
• Dunbar CA, Morgan B, Van Oort M, et al. A comparison of dry powder inhaler dose delivery characteristics using a power criterion. PDA J Pharm Sci Technol. 2000;54(6):478–484.
   PubMedGoogle Scholar
• Hira D, Okuda T, Ichihashi M, et al. Influence of peak inspiratory flow rates and pressure drops on inhalation performance of dry powder inhalers. Chem Pharm Bull (Tokyo). 2012;60(3):341–347.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1417.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Price D. What you need to know about inhalers and how to use them. Prescriber. 2009;20:47–52.
   Google Scholar
• Stokes GG. On the effect of the internal friction of fluids on the motion of pendulums. Mathematical and Physical Papers. Cambridge University Press. 2009; 1–10. doi: 10.1017/CBO9780511702266.002.
   Google Scholar
• Weers JG, Son Y-J, Glusker M, et al. Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract? J Aerosol Med Pulm Drug Deliv. 2019;32(2):55–69.
   PubMed Web of Science ®Google Scholar
• Cheng YS. Aerosol deposition in the extrathoracic region. Aerosol Sci Technol. 2003;37(8):659–671.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.
   PubMed Web of Science ®Google Scholar
• Clark AR, Weers JG, Dhand R. The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates. J Aerosol Med Pulm Drug Deliv. 2020;33(1):1–11.
   PubMed Web of Science ®Google Scholar
• Spiriva Patient information leaflet.
   Google Scholar
• Sahay S, Holy R, Lyons S, et al. Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOSTM dry powder inhaler device. Pulm Circ. 2021;11(1):1–9.
   Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100.
   PubMedGoogle Scholar
• Azouz W, Chetcuti P, Hosker HSR, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28(1):35–42.
   PubMed Web of Science ®Google Scholar
• Haikarainen J, Vahteristo M, Lähelmä S, et al. Patient inspiratory maneuver performance; peak lungpower, acceleration and volume. J Aerosol Med Pulm Drug Deliv. 2020;33(6):305–313.
   PubMed Web of Science ®Google Scholar
• Delvadia RR, Wei X, Longest PW, et al. In vitro tests for aerosol deposition. IV: simulating variations in human breath profiles for realistic DPI testing. J Aerosol Med Pulm Drug Deliv. 2016;29(2):196–206.
   PubMed Web of Science ®Google Scholar
• Lexmond AJ, Hagedoorn P, Frijlink HW, et al. Prerequisites for a dry powder inhaler for children with cystic fibrosis. PLoS One. 2017;12(8):e0183130.
   PubMed Web of Science ®Google Scholar
• Bagherisadeghi G, Larhrib EH, Chrystyn H. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort® Turbuhaler®. Int J Pharm. 2017;522(1–2):137–146.
   PubMedGoogle Scholar
• Krüger P, Ehrlein B, Michael Zier RG, et al. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J. 2014;44(Supp: 58, 4635).
   Google Scholar
• Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75.
   PubMed Web of Science ®Google Scholar
• Pohlmann G, Hohlfeld JM, Haidl P, et al. Assessment of the power required for optimal use of current inhalation devices. J Aerosol Med Pulm Drug Deliv. 2018;31(6):339–346.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387.
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Everard ML, Haikarainen J, et al. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). J Aerosol Med Pulm Drug Deliv. 2014;27:329–340.
   PubMed Web of Science ®Google Scholar
• Delvadia R, Hindle M, Longest PW, et al. In vitro tests for aerosol deposition II: IVIVCS for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2013;26(3):138–144.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus ® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, et al. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595.
   PubMed Web of Science ®Google Scholar
• Chen S-Y, Huang C-K, Peng H-C, et al. Inappropriate peak inspiratory flow rate with dry powder inhaler in chronic obstructive pulmonary disease. Sci Rep. 2020;10(7271).
   Google Scholar
• Buttini F, Brambilla G, Copelli D, et al. Effect of flow rate on in vitro aerodynamic performance of NEXThaler ® in comparison with Diskus ® and Turbohaler ® dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2016;29(2):167–178.
   PubMed Web of Science ®Google Scholar
• Price DB, Yang S, Wan Yau Ming S, et al. Physiological predictors of peak inspiratory flow using observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2018;13:3937–3946.
   PubMed Web of Science ®Google Scholar
• Haughney J, Lee AJ, McKnight E, et al. Peak inspiratory flow measured at different inhaler resistances in patients with asthma. J Allergy Clin Immunol Pract. 2021;9(2):890–896.
   PubMed Web of Science ®Google Scholar
• Jõgi R, Mattila L, Vahteristo M, et al. Inspiratory flow parameters through dry powder inhalers in healthy volunteers and patients with Chronic Obstructive Pulmonary Disease (COPD): device resistance does not limit use in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1193–1201.
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Pelkonen AS, Vartiainen V, et al. Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials. J Thorac Dis. 2021;13(2):621–631.
   PubMed Web of Science ®Google Scholar
• Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456–465.
   PubMedGoogle Scholar
• ADACHI YS, ADACHI Y, Itazawa T, et al. Ability of preschool children to use dry powder inhalers as evaluated by in-check meter. Pediatr Int. 2006;48(1):62–65.
   PubMed Web of Science ®Google Scholar
• Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol. 2005;39(5):447–451.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020.
   Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179.
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, et al. Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI. Eur J Clin Pharmacol. 2005;60:837–841.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Herodotou Y, Tomos I, et al. Ability of using different dry powder inhalers during COPD exacerbations. Pulm Pharmacol Ther. 2018;48:211–216.
   PubMed Web of Science ®Google Scholar
• Bentur L, Mansour Y, Hamzani Y, et al. Measurement of inspiratory flow in children with acute asthma. Pediatr Pulmonol. 2004;38(4):304–307.
   PubMed Web of Science ®Google Scholar
• van Geffen WH, Douma WR, Slebos DJ, et al. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016;2016(8). DOI:10.1002/14651858.CD011826.pub2
   PubMedGoogle Scholar
• Seberová E, Oxis AA. (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000;94(6):607–611.
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med. 2003;97(9):1067–1074.
   PubMed Web of Science ®Google Scholar
• Balanag VM, Yunus F, Yang P-C, et al. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther. 2006;19(2):139–147.
   PubMed Web of Science ®Google Scholar
• Rubinfeld AR, Scicchitano A, Hunt A, et al. Formoterol Turbuhaler as reliever medication in patients with acute asthma. Eur Respir J. 2006;27(4):735–741.
   PubMed Web of Science ®Google Scholar
• Chew KS, Kamarudin H, Hashim CW. A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks. Int J Emerg Med. 2012;5(16). DOI:10.1186/1865-1380-5-16
   PubMedGoogle Scholar
• Morice AH, Peterson S, Beckman O, et al. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract. 2007;61(11):1874–1883.
   PubMed Web of Science ®Google Scholar
• Singh D, Berg F, Leaker B, et al. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: a noninferiority study using metered dose vs dry powder inhaler. Br J Clin Pharmacol. 2019;85(4):729–736.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Huchon G, Leclerc V, et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005;72(Suppl 1):6–12.
   PubMedGoogle Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide–formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030.
   PubMed Web of Science ®Google Scholar
• Brusasco V, Canonica GW, Negro RD, et al. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv. 2011;24(5):235–243.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Geri P, Luperini M, et al. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. Br J Clin Pharmacol. 2004;58(5):512–520.
   PubMed Web of Science ®Google Scholar
• Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med. 2007;101(12):2464–2471.
   PubMed Web of Science ®Google Scholar
• Najafizadeh K, Sohrab Pour H, Ghadyanee M, et al. A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emerg Med J. 2007;24(5):317–321.
   PubMed Web of Science ®Google Scholar
• Direkwatanachai C, Teeratakulpisarn J, Suntornlohanakul S, et al. Comparison of salbutamol efficacy in children–via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer–in mild to moderate asthma exacerbation: a multicenter, randomized study. Asian Pac J Allergy Immunol. 2011;29(1):25–33.
   PubMed Web of Science ®Google Scholar
• Raimondi AC, Schottlender J, Lombardi D, et al. Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Chest. 1997;112(1):24–28.
   PubMed Web of Science ®Google Scholar
• Lodha R, Gupta G, Baruah BP, et al. Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial. Indian Pediatr. 2004;41(1):15–20.
   PubMedGoogle Scholar